BiotechTube
Vesper Medical

Vesper Medical

Wayne, United States· Est.
vespermedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Vesper Medical is a private, clinical-stage medical device company developing specialized stents for deep venous disease, specifically Chronic Venous Insufficiency (CVI). Its lead program, the Vesper DUO Venous Stent System, is under investigation in the VIVID clinical trial, which has completed patient enrollment. The company was founded in 2017 as a spinout from Intact Vascular and was subsequently acquired by Royal Philips, providing strategic backing and a pathway to commercialization within a larger medtech portfolio.

Chronic Venous InsufficiencyVascular Disease

Technology Platform

A next-generation, modular venous stent platform consisting of the DUO-HYBRID and DUO-EXTEND stents, uniquely engineered to address anatomical challenges (compression, large diameters, long lesions) in the iliac and common femoral veins.

Opportunities

The acquisition by Philips provides immense global commercial scale, R&D resources, and synergistic potential with Philips' image-guided therapy systems.
The dedicated venous stent market is large, underpenetrated, and growing rapidly due to high unmet need and increasing disease awareness, offering a significant growth runway.

Risk Factors

The company faces clinical and regulatory risk pending the outcome of the VIVID trial.
Post-acquisition integration into Philips and achieving market adoption against established competitors in a market accustomed to using arterial stents for venous applications present significant commercialization challenges.

Competitive Landscape

Vesper competes in the dedicated venous stent market against large, established medical device companies including BD (Bard), Boston Scientific (VICI, Venovo), and Medtronic (Abre). Its key differentiator is its modular DUO portfolio designed specifically for iliofemoral anatomy, but it must overcome strong incumbent market positions and physician familiarity with existing products.

More companies in Drug Delivery & Formulation →More companies in United States →